biostudies-literatureUnknown39(8)Wang SThe rapidly spreading Omicron variant is highly resistant to vaccines, convalescent sera, and neutralizing antibodies (nAbs), highlighting the urgent need for potent therapeutic nAbs. Here, a panel of human nAbs from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent patients show diverse neutralization against Omicron, of which XMA01 and XMA04 maintain nanomolar affinities and excellent neutralization (half maximal inhibitory concentration [IC50]: ∼20 ng/mL). nAb XMA09 shows weak but unattenuated neutralization against all variants of concern (VOCs) as well as SARS-CoV. Structural analysis reveals that the above three antibodies could synergistically bind to the receptor-binding domains (RBDs) of both wild-type and Omicron spikes and defines the critical determinantCell reports110862https://www.ebi.ac.uk/biostudies/studies/S-EPMC9080080biostudies-literatureThree SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.PMC9080080Tang ZZheng ZLiu LZhang JYuan QYuan LZheng QYu HCheng TGuan YZhang THuang YLi SLi TChen ZWang SZhang YYing DXia NChen XLiu CSun HWang YXiong HfalseThree SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.The rapidly spreading Omicron variant is highly resistant to vaccines, convalescent sera, and neutralizing antibodies (nAbs), highlighting the urgent need for potent therapeutic nAbs. Here, a panel of human nAbs from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent patients show diverse neutralization against Omicron, of which XMA01 and XMA04 maintain nanomolar affinities and excellent neutralization (half maximal inhibitory concentration [IC50]: ∼20 ng/mL). nAb XMA09 shows weak but unattenuated neutralization against all variants of concern (VOCs) as well as SARS-CoV. Structural analysis reveals that the above three antibodies could synergistically bind to the receptor-binding domains (RBDs) of both wild-type and Omicron spikes and defines the critical determinant2022-01-01T00:00:00Z2022 May2026-05-31T05:03:59.828Z2025-02-19T01:54:56.63ZS-EPMC90800803559486910.1016/j.celrep.2022.110862